case_images: PMC7104315_01
case_images: Ultrasound image showing 9 mm right testicular calcified lesion.
case_images: CRIPA2020-5279013.001.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.001.jpg
case_images: fig1
case_images: An ultrasonography evaluation revealed grade 3 left varicocele and an incidental 9 mm right testicular calcified lesion (Figure 1).
case_images: Well-circumscribed mass of LCCSCT (H&E stain; x10).
case_images: CRIPA2020-5279013.002.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.002.jpg
case_images: fig2
case_images: Histopathological assessment findings showed a well-circumscribed, encapsulated tumor composed of amorphous calcified areas, surrounded by tumor cells (Figure 2).
case_images: Psammomatous calcification within the neoplastic nests (H&E stain; x10).
case_images: CRIPA2020-5279013.003.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.003.jpg
case_images: fig3
case_images: Tumor cells were large and oval to polygonal in shape, with a highly eosinophilic granulated cytoplasm (Figure 3).
case_images: LCCSCT shows a myxoid stromal component (H&E stain; x20).
case_images: CRIPA2020-5279013.004.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.004.jpg
case_images: fig4
case_images: Nuclear pleomorphism was prominent, but mitotic activity was rare and there was no evidence of necrosis (Figure 4).
case_images: LCCSCT cells show strong inhibin expression (x10).
case_images: CRIPA2020-5279013.005.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.005.jpg
case_images: fig5
case_images: Tumor cells were positive for inhibin alpha, epithelial membrane antigen (EMA), calretinin, S-100, MART-1, and vimentin and negative for CD99 (AKA MIC2), pan-cytokeratin (AE1/3), synaptophysin, chromogranin, CK8/18, and CD10 (Figures 5-9).
case_images: LCCSCT cells show intense calretinin expression (x10).
case_images: CRIPA2020-5279013.006.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.006.jpg
case_images: fig6
case_images: Tumor cells were positive for inhibin alpha, epithelial membrane antigen (EMA), calretinin, S-100, MART-1, and vimentin and negative for CD99 (AKA MIC2), pan-cytokeratin (AE1/3), synaptophysin, chromogranin, CK8/18, and CD10 (Figures 5-9).
case_images: LCCSCT cells show intense vimentin expression (x4).
case_images: CRIPA2020-5279013.007.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.007.jpg
case_images: fig7
case_images: Tumor cells were positive for inhibin alpha, epithelial membrane antigen (EMA), calretinin, S-100, MART-1, and vimentin and negative for CD99 (AKA MIC2), pan-cytokeratin (AE1/3), synaptophysin, chromogranin, CK8/18, and CD10 (Figures 5-9).
case_images: LCCSCT cells show strong Mart-1 expression (x20).
case_images: CRIPA2020-5279013.008.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.008.jpg
case_images: fig8
case_images: Tumor cells were positive for inhibin alpha, epithelial membrane antigen (EMA), calretinin, S-100, MART-1, and vimentin and negative for CD99 (AKA MIC2), pan-cytokeratin (AE1/3), synaptophysin, chromogranin, CK8/18, and CD10 (Figures 5-9).
case_images: LCCSCT cells show strong S100 expression (x20).
case_images: CRIPA2020-5279013.009.jpg
case_images: PMC7104315_01_CRIPA2020-5279013.009.jpg
case_images: fig9
case_images: Tumor cells were positive for inhibin alpha, epithelial membrane antigen (EMA), calretinin, S-100, MART-1, and vimentin and negative for CD99 (AKA MIC2), pan-cytokeratin (AE1/3), synaptophysin, chromogranin, CK8/18, and CD10 (Figures 5-9).